According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Other equities analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of GRIFOLS S A/S from a sell rating to a hold rating in a research report on Saturday, December 22nd. Berenberg Bank cut shares of GRIFOLS S A/S from a buy rating to a hold rating in a research report on Friday, February 8th. Finally, Morgan Stanley cut their target price on shares of GRIFOLS S A/S from $20.00 to $19.00 and set an underweight rating for the company in a research report on Wednesday, January 2nd. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $21.00.
A number of institutional investors and hedge funds have recently made changes to their positions in GRFS. Deutsche Bank AG raised its position in GRIFOLS S A/S by 670.3% during the fourth quarter. Deutsche Bank AG now owns 12,427,277 shares of the biotechnology company’s stock worth $228,164,000 after acquiring an additional 10,813,901 shares during the last quarter. Norges Bank acquired a new position in shares of GRIFOLS S A/S in the fourth quarter valued at approximately $57,748,000. AKO Capital LLP raised its position in shares of GRIFOLS S A/S by 24.7% in the fourth quarter. AKO Capital LLP now owns 12,283,473 shares of the biotechnology company’s stock valued at $225,525,000 after buying an additional 2,436,502 shares during the last quarter. Morgan Stanley raised its position in shares of GRIFOLS S A/S by 131.5% in the third quarter. Morgan Stanley now owns 1,103,016 shares of the biotechnology company’s stock valued at $23,571,000 after buying an additional 626,527 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in shares of GRIFOLS S A/S by 177.8% in the third quarter. Envestnet Asset Management Inc. now owns 712,787 shares of the biotechnology company’s stock valued at $15,232,000 after buying an additional 456,223 shares during the last quarter. Institutional investors own 19.96% of the company’s stock.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Story: Roth IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.